Company Profiles

driven by the PitchBook Platform

Actinobac Biomed

Description

Developer of pharmaceutical technologies designed to target white blood cell diseases. The company's pharmaceutical technologies develop agents for the treatment of hematologic malignancies (leukemias & lymphomas), latent infections (HIV/AIDS & tuberculosis) and autoimmune diseases (rheumatoid arthritis, multiple sclerosis, Crohn's disease, type 1 diabetes, Lupus & psoriasis) based upon the natural biologic agent leukotoxin (Leukothera), which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells., providing consumers with Leukotoxin as a protein therapeutic for the treatment of hematologic malignancies.

2009

Founded

PRIVATE

Status

1-10

Employees

Grant

Latest Deal Type

$905k

Latest Deal Amount

$1.1M

Total Amount Raised

Description

Developer of pharmaceutical technologies designed to target white blood cell diseases. The company's pharmaceutical technologies develop agents for the treatment of hematologic malignancies (leukemias & lymphomas), latent infections (HIV/AIDS & tuberculosis) and autoimmune diseases (rheumatoid arthritis, multiple sclerosis, Crohn's disease, type 1 diabetes, Lupus & psoriasis) based upon the natural biologic agent leukotoxin (Leukothera), which targets Leukocyte Function Antigen-1 (LFA-1) on white blood cells., providing consumers with Leukotoxin as a protein therapeutic for the treatment of hematologic malignancies.

Website:

www.actinobac.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Therapeutic Devices

Other Industries

Pharmaceuticals
Biotechnology

Primary Office

15 Pelham Road Kendall Park, NJ 08824United States +1 (732) 371-2694
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Actinobac Biomed's full profile, request a free trial.

    Actinobac Biomed Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Actinobac Biomed Investors (2)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Foundation Venture Capital GroupVenture CapitalMinority000 0000000 0000
    National Cancer InstituteGovernment000 0000000 0000
    Foundation Venture Capital Group Venture Capital
    National Cancer Institute Government

    Actinobac Biomed Executive Team (1)

    NameTitleBoard
    Seat
    Contact
    Info
    Benjamin Belinka Ph.DPresident & Chief Executive Officer
    Benjamin Belinka Ph.D President & Chief Executive Officer

    Actinobac Biomed Board Members (1)

    NameRepresentingRoleSinceContact
    Info
    Scott Kachlany Ph.DSelfFounder, Chief Scientific Officer & Chairman, Scientific Advisory000 0000
    Scott Kachlany Ph.D Founder, Chief Scientific Officer & Chairman, Scientific Advisory Self
    Request full access to PitchBook